Medicus Pharma submits EU CTIS application to amend Teverelix Phase 2b trial plan

Medicus Pharma

Medicus Pharma

MDCX

0.00
  • Medicus Pharma filed a substantial modification via the EU CTIS to support a planned Phase 2b Teverelix study in advanced prostate cancer.
  • The application is under regulatory review; enrollment is targeted for later this year, subject to authorization.
  • The trial is intended to support registrational planning focused on prostate cancer patients with elevated cardiovascular risk on androgen deprivation therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606080730PRIMZONEFULLFEED9733033) on June 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.